BLUE bluebird bio, Inc. Loading...

From VRTX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
20:30
May 04 ◎
Duncan McKechnie VRTX Q1 FY26 call
Vertex reached pricing agreement for Casgevi in Germany in Q1, a historic moment for the treatment, indicating successful reimbursement negotiations in a major European market. — This de-risks the European rollout for Casgevi and could pressure competitors' pricing strategies in the ex-US gene therapy market.
BLUE
MED

About BLUE Analyst Coverage

Buzzberg tracks BLUE (bluebird bio, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Duncan McKechnie.